Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Martini

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Nature Communications|October 22, 2020
Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemiaLei Jiang, Ji-Sun Park, Ling Yin, et al.
Journal of Hepatology|December 19, 2020
Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4<sup>-/-</sup> mouse model of PFIC3Guangyan Wei, Jingsong Cao, Pinzhu Huang, et al.
BMC Immunology|August 24, 2010
Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseasesPaolo G V Martini, Lynette C Cook, Scott Alderucci, et al.
Journal of Translational Medicine|January 28, 2025
FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitisAmaya Lopez-Pascual, Eva Santamaria, Nuria Ardaiz, et al.
Nature Medicine|October 10, 2018
Systemic messenger RNA as an etiological treatment for acute intermittent porphyriaLei Jiang, Pedro Berraondo, Daniel Jericó, et al.
American Journal of Human Genetics|August 22, 2023
GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individualsMenno Ter Huurne, Benjamin L Parker, Ning Qing Liu, et al.
Clinical Science (London, England : 1979)|September 20, 2024
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)Amaya Lopez-Pascual, Joan S Russo-Cabrera, Nuria Ardaiz, et al.
Cell Reports|August 30, 2018
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic AcidemiaDing An, Jessica L Schneller, Andrea Frassetto, et al.
Cell Reports|December 21, 2017
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic AcidemiaDing An, Jessica L Schneller, Andrea Frassetto, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 7, 2019
mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin DeficiencyJingsong Cao, Ding An, Mikel Galduroz, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Nature Communications|October 22, 2020
Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemiaLei Jiang, Ji-Sun Park, Ling Yin, et al.
Journal of Hepatology|December 19, 2020
Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4<sup>-/-</sup> mouse model of PFIC3Guangyan Wei, Jingsong Cao, Pinzhu Huang, et al.
BMC Immunology|August 24, 2010
Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseasesPaolo G V Martini, Lynette C Cook, Scott Alderucci, et al.
Journal of Translational Medicine|January 28, 2025
FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitisAmaya Lopez-Pascual, Eva Santamaria, Nuria Ardaiz, et al.
Nature Medicine|October 10, 2018
Systemic messenger RNA as an etiological treatment for acute intermittent porphyriaLei Jiang, Pedro Berraondo, Daniel Jericó, et al.
American Journal of Human Genetics|August 22, 2023
GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individualsMenno Ter Huurne, Benjamin L Parker, Ning Qing Liu, et al.
Clinical Science (London, England : 1979)|September 20, 2024
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)Amaya Lopez-Pascual, Joan S Russo-Cabrera, Nuria Ardaiz, et al.
Cell Reports|August 30, 2018
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic AcidemiaDing An, Jessica L Schneller, Andrea Frassetto, et al.
Cell Reports|December 21, 2017
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic AcidemiaDing An, Jessica L Schneller, Andrea Frassetto, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 7, 2019
mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin DeficiencyJingsong Cao, Ding An, Mikel Galduroz, et al.
Pageof 12